A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma
- Determine the sensitivity, specificity, and accuracy of fludeoxyglucose F 18 (FDG)
positron emission tomography (PET) as compared to conventional imaging in determining
the extent of disease in women with primary or recurrent breast cancer.
- Determine how often clinical management and operative intervention plans for patients
are altered based on these FDG-PET scan findings.
- Determine whether FDG-PET results in more accurate detection of disease in these
OUTLINE: Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients
undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6
PROJECTED ACCRUAL: (50 with primary disease and 50 with recurrent disease) will be accrued
for this study within 1-2 years.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Determine the sensitivity, specificity, and accuracy
Elisa Rush Port, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|